“Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial”. 2023. SKIN The Journal of Cutaneous Medicine 7 (6): s239. https://doi.org/10.25251/skin.7.supp.239.